Modular Medical (NASDAQ:MODD) versus Sanara MedTech (NASDAQ:SMTI) Head-To-Head Comparison

Modular Medical (NASDAQ:MODD) and Sanara MedTech (NASDAQ:SMTI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends and earnings.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Modular Medical and Sanara MedTech, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Modular Medical	1	0	0	0	1.00
Sanara MedTech	1	1	2	0	2.25

Sanara MedTech has a consensus target price of $34.00, indicating a potential upside of 71.72%. Given Sanara MedTech’s stronger consensus rating and higher probable upside, analysts plainly believe Sanara MedTech is more favorable than Modular Medical.

Earnings & Valuation

This table compares Modular Medical and Sanara MedTech”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Modular Medical	N/A	N/A	-$18.82 million	($14.71)	-0.34
Sanara MedTech	$103.12 million	1.76	-$37.56 million	($4.23)	-4.68

Modular Medical has higher earnings, but lower revenue than Sanara MedTech. Sanara MedTech is trading at a lower price-to-earnings ratio than Modular Medical, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Modular Medical has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500. Comparatively, Sanara MedTech has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500.

Profitability

This table compares Modular Medical and Sanara MedTech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Modular Medical	N/A	-245.85%	-190.80%
Sanara MedTech	-36.42%	-20.73%	-5.14%

Insider & Institutional Ownership

27.5% of Modular Medical shares are owned by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are owned by institutional investors. 7.1% of Modular Medical shares are owned by insiders. Comparatively, 42.6% of Sanara MedTech shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Sanara MedTech beats Modular Medical on 9 of the 13 factors compared between the two stocks.

About Modular Medical

Modular Medical, Inc. operates as a medical device company. It focuses on the design, development, and commercialization of insulin pumps. It offers MODD1, a two-part patch pump for type-1 and type-2 diabetes. The company is headquartered in San Diego, California.

About Sanara MedTech

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.